Heel's 75 Years Anniversary

As the global market leader for homeopathic combination medications, regularly producing some 90 million ampules, 320 tons of oral liquids, 350 tons of ointments and gels, and around a billion tablets, and represented in over 50 countries worldwide, Biologische Heilmittel Heel GmbH also carries out pioneering research into natural medicine.

Pioneer of Scientific Research Into Natural Medicine

Biologische Heilmittel Heel, which was founded in Berlin in 1936 by physician and homeopath Dr. Hans-Heinrich Reckeweg, relocated to Baden-Baden in 1954. Nine years later the family business moved to its current location in the district of Oos in Baden-Baden, Germany. Heel has been owned by DELTON AG since 1977.

The company name is an acronym made up of the initial letters of the Latin “Herba est ex luce” – “Plants derive their healing power from light”. This is because both naturalness and science-based medical research have been guiding principles for Heel from the very outset. Reckeweg’s spirit of research laid the foundations for the outstandingly successful Heel products.

Heel medications based on the principles of bioregulating medicine, activate the body’s self-healing capability naturally and help to establish a healthy equilibrium.

At the same time, the prove of efficacy of Heel medications according to scientific standards was a major goal of the company founder. Consequently, Heel is pre-eminent in systematically conducting research on basic principles and modes of action of natural medicine. The company invests several tens of millions of euros every year in science-based medical research and will further expand this commitment.

Global Market Leader for Homeopathic Combination Medications

Right back in the very earliest years of the company numerous medications were developed which are core products in the corporate portfolio to this very day: Angin-Heel® or Gripp-Heel®. Over the years the range of combination medications has been steadily expanded. Today over 700 homeopathic combination medications for human and animal medicine are produced in more than 4500 country-specific packagings. These include market leaders such as Traumeel® and other strong brands such as Neurexan®.

Since the mid 1960s Heel has gradually been expanding its international activities and now has eleven subsidiaries in countries worldwide, including Brazil, Canada, Chile, and Poland. In addition, Heel medications are available in over 50 countries via distribution partners, with tendency to rise. Even though some 70 percent of the company’s sales are achieved in international markets, Germany remains the largest market. Consequently, the company is still headquartered in Baden-Baden where around 800 of Heel’s total workforce of 1300 employees are based.